Case Report

Patient with Markedly Elevated CA 19-9 Not Associated with Malignancy

Authors: Douglas Lowe, MD, Jeffrey Lee, MD, Robert Schade, MD, FACG, FACP, Ayaz Chaudhary, MD, FACG, FACP

Abstract

A 66-year-old white male presented with jaundice, pruritus, and a 30-pound weight loss over two months. Physical examination revealed scleral icterus. Laboratory evaluation revealed ALT 161 U/L, AST 290 U/L, alkaline phosphatase 2004 U/L, GGT 2,552 U/L, total bilirubin 10.2 mg/dL, and a carbohydrate antigen 19-9 (CA 19-9) level of 4,374 U/mL. Initial endoscopic retrograde cholangiopancreatography (ERCP) was unsuccessful due to ulceration in the duodenum healed with esomeprazole therapy. Subsequent ERCP showed a possible filling defect in the common bile duct treated with sphincterotomy and balloon sweeping of the common bile duct. Symptoms and jaundice resolved five months after initial presentation with normal labs and studies.


While elevated CA 19-9 levels occur in most patients with carcinoma of the pancreas, it can also be elevated in patients with extrapancreatic malignancies and acute cholangitis. This case illustrates the fact that a markedly elevated CA 19-9 can be secondary to causes other than carcinoma.


Key Points


* CA 19-9 has been considered by some to be the “gold” standard serologic marker for the diagnosis of patients with pancreatic cancer.


* While elevated CA 19-9 levels occur in most patients with carcinoma of the pancreas, it can also be elevated in patients with extrapancreatic malignancies and acute cholangitis.


* Markedly elevated CA 19-9 levels can be secondary to causes other than carcinoma.

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Steinberg W. The clinical utility of the CA 19-9 tumor-associated antigen. Am J Gastroenterol1990;84:350–355.
 
2. Gansauge S, Gansauge F, Beger HG. Molecular oncology in pancreatic cancer. J Mol Med1996;74:313–320.
 
3. Koprowski H, Steplewski Z, Mitchell K, et al. Colorectal carcinoma antigens detected by hybridoma antibodies. Somatic Cell Genet 1979;5:957–971.
 
4. Koprowski H, Herlyn M, Steplewski Z, et al. Specific antigen in serum of patients with colon carcinoma. Science 1981;212:53–55.
 
5. DelVillano BC, Brennan S, Brock P, et al. Radioimmunometric assay for a monoclonal antibody-defined tumor marker, CA 19-9. Clin Chem 1983;29:549–552.
 
6. Ritts RE Jr, DelVillano BC, Go VL, et al. Initial clinical evaluation of an immunoradiometric assay for CA 19-9 using NCI serum bank. Int J Cancer 1984;33:339–345.
 
7. Ritts RE Jr, Nagorney DM, Jacobsen DJ, et al. Comparison of preoperative serum CA19-9 levels with results of diagnostic imaging modalities in patients undergoing laparotomy for suspected pancreatic or gallbladder disease. Pancreas 1994;9:707–716.
 
8. Craxi A, Patti C, Aragona E. Serum CA 19-9 levels in patients with hepatocelluar carcinoma or cirrhosis. Ital J Gastroenterol 1985;17:288–289.
 
9. Albert MB, Steinberg WM, Henry JP. Elevated serum levels of tumor marker CA 19-9 in acute cholangitis. Dig Dis Sci 1988;33:1223–1225.
 
10. Smanio T. Proposed nomenclature and classification of the human pancreatic ducts and duodenal papillae: study based on 200 post mortems. Int Surg 1969;52:125–141.
 
11. Stimec B, Bulajic M, Korneti V, et al. Ductal morphometry of ventral pancreas in pancreas divisum: comparison between clinical and anatomical results. Ital J Gastroenterol 1996;28:76–80.
 
12. Outtas O, Barthet M, De Troyer J, et al. [Pancreatic panniculitis with intraductal carcinoid tumor of pancreas divisum]. Ann Dermatol Venereol 2004;131:466–469.
 
13. Martin Fernandez J, Ratia T, Gutierrez A, et al. Intraductal pancreatic carcinoma associated with pancreas divisum. Rev Esp Enferm Dig 2003;95:358–363.
 
14. Hunerbein M, Ghadimi BM, Benhidjeb T, et al. A rare malformation of the pancreaticobiliary junction long common channel cholechochal cyst and pancreas divisum in a patient with pancreatic cancer.Hepato-gastroenterology 1999;46:1647–1649.
 
15. Lehman GA, Sherman S. Anatomy and clinical significance of pancreas divisum. In: Rose BD (ed),UpToDate, Wellesley, MA, 2004.